Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Capman funds in connection with the sale of Proxima
Mandate

Vinge advises Capman funds in connection with the sale of Proxima

May 05, 2011

Vinge has advised funds managed by CapMan in connection with the sale of Proxima. Proxima is a private healthcare provider conducting high quality primary care, diagnostics, specialist care, rehabilitation and occupational healthcare operations. The operations are primarily conducted in the Stockholm although the company also has centres in Uppsala, and the Östergötland and Skåne regions. The transaction is subject to approval by the competent competition authorities.

Vinge’s team consisted of partner Jan Byström together with, among others, associates Martin Hall, Anna-Sofia Nilsson Prevell, Malin Buch and project assistants Pernilla Warg and Mikaela Mars. Partner Marcus Glader provided competition law advice.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026